Brain injury obesity drug gets extended safety test
NCT ID NCT07156578
Summary
This study continues testing an experimental drug called bivamelagon for people with obesity caused by damage to a specific brain area (hypothalamus). It follows 25 participants for up to 2 years to check long-term safety and see if the drug helps control weight and improve quality of life. All participants have already safely completed an earlier phase of this research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOTHALAMIC OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Birmingham Women's and Children's NHS Foundation Trust
Birmingham, B15 2TG, United Kingdom
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Columbia University
New York, New York, 10027, United States
-
Great Ormond Street Hospital for Children
London, WC1N 3JH, United Kingdom
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
University of Cambridge
Cambridge, CB2 1TN, United Kingdom
-
University of Iowa Children's Hospital
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.